Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Kyverna Therapeutics reported its second quarter 2026 financial results and provided a business update, highlighting significant progress in its miv-cel neuroimmunology franchise. The company received RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, is on track to complete its rolling BLA submission …